Reconsidering Standard of Care for Hypercortisolism

Author(s):

Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE,Ralph DeFronzo, MD

Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.

EP: 1.Overview of the CATALYST Study for Hypercortisolism

EP: 2.Defining Difficult to Control Diabetes

EP: 3.CATALYST Trial Study Design

EP: 4.True Prevalence of Hypercortisolism

EP: 5.Coexisting Cardiometabolic Conditions and Hypercortisolism

EP: 6.Engaging Primary Care Clinicians in Screening for Hypercortisolism

EP: 7.Spectrum of Hypercortisolism Presentations

EP: 8.Mifeprestone for Treatment of Hypercortisolism

Now Viewing

EP: 9.Reconsidering Standard of Care for Hypercortisolism

Video content above is prompted by the following:

For patients undergoing treatment for hypercortisolism, what are the long-term implications for glycemic control and overall health?
How might future findings from this study influence the standard of care for patients with difficult-to-control T2D?
Part 2 of this study is currently ongoing. In the meantime, how should clinicians be approaching patients who meet these criteria right now?